Lifeward Ltd. announced on April 29, 2025, that a major U.S. health insurance company has approved payment for a ReWalk 7 Personal Exoskeleton for one of its beneficiaries. This marks the first approval for payment of the newly launched ReWalk 7 by a large commercial health insurer in the U.S.
This decision is a significant step in expanding access for individuals with spinal cord injury (SCI) to Lifeward's personal exoskeleton technology. Commercial health insurers cover a substantial portion of individuals with SCI in the United States.
The approval demonstrates momentum in Lifeward's efforts to engage with commercial health insurers, building on the Medicare reimbursement pathway finalized in 2024. This precedent is expected to solidify a growth trajectory for the company by broadening market access.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.